1. Home
  2. AACG vs LIXT Comparison

AACG vs LIXT Comparison

Compare AACG & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AACG

ATA Creativity Global

HOLD

Current Price

$1.25

Market Cap

32.7M

Sector

Real Estate

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$3.75

Market Cap

26.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AACG
LIXT
Founded
1999
2005
Country
China
United States
Employees
N/A
3
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.7M
26.5M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
AACG
LIXT
Price
$1.25
$3.75
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.1K
40.8K
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$0.64
52 Week High
$2.58
$6.09

Technical Indicators

Market Signals
Indicator
AACG
LIXT
Relative Strength Index (RSI) 69.59 63.83
Support Level $1.09 $3.68
Resistance Level $1.36 $4.45
Average True Range (ATR) 0.10 0.30
MACD 0.02 0.09
Stochastic Oscillator 58.18 76.22

Price Performance

Historical Comparison
AACG
LIXT

About AACG ATA Creativity Global

ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: